This grant opportunity, PAR-24-279 (CFDA: 93.846), funds exploratory clinical trials in arthritis, musculoskeletal, and skin diseases. It requires an R61 clinical trial.
Want the full details?
Sign up free to see the agency name and the original bid posting link, plus contracting-officer contacts and AI response outlines. Every feature is free through December 31, 2026.